PCRX Stock Analysis: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$20.54
0.45 (2.24%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
25d
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PCRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PCRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.68
Based on 9.7% avg growth
INTRINSIC VALUE TODAY
$23.39
12.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $20.54, which is considered oversold relative to its 30-day fair value range of $21.17 to $26.26. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.9) compared to its historical average (7.0). Remarkably, the market is currently pricing in an annual earnings decline of 5.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PCRX is in a downtrend. The price is approaching resistance at $21.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PCRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $29.71 (+47.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PCRX is in a downtrend. The price is approaching resistance at $21.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PCRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $29.71 (+47.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$21.17 -
$26.26
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding PCRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 47.9% below Wall St target ($29.71)
Fair Price Analysis
30-Day Fair Range
$21.17 -
$26.26
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$18.80
Resistance Level
$21.12
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
5.90
Wall Street Target
$29.71
(+47.9%)
Revenue Growth (YoY)
6.5%
Earnings Growth (YoY)
-47.8%
Profit Margin
3.0%
Valuation Discount vs History
-5.5% cheaper
PE vs Historical
5.9 vs 7.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.5%
(market-implied from PE analysis)
1-Year Target
$18.99
(-6%)
2-Year Target
$17.94
(-11%)
3-Year Target
$16.95
(-16%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$20.13
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 15.3%)
$116.49
(+480%)
Base:
(SPY PE: 5.9, Growth: 15.3%)
$30.80
(+53%)
Bear:
(PE: 5.0, Growth: 15.3%)
$26.18
(+30%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (43x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 43.36 | Current EPS (TTM): $0.47
Bull Case
$44.84
(+118%)
Analyst growth 100.0%, PE expands to 47.7
Base Case
$40.76
(+98%)
Market implied 100.0%, PE stable at 43.4
Bear Case
$13.86
(-33%)
Severe decline -20.0%, PE contracts to 36.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.9 to 7.0
Stabilization Target:
$23.85
(+18.7%)
PE Expansion Potential:
+18.7%
Last updated: January 31, 2026 12:02 AM ET
Data refreshes hourly during market hours. Next update: 1:02 AM
Data refreshes hourly during market hours. Next update: 1:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Marcelo Bigal
SELL
4912 shares
2025-08-07
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced PCRX Option Strategies
Professional options setups generated by AI based on today's PCRX price and gamma walls.
